Pregnancies in kidney transplant recipients with complement gene variant-mediated thrombotic microangiopathy.

atypical haemolytic uraemic syndrome complement system delivery eculizumab gravidity kidney transplant recipient neonate pregnancy pregnancy-associated complement gene variant-mediated thrombotic microangiopathy thrombotic microangiopathy

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 31 01 2020
revised: 30 04 2020
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 13 4 2021
Statut: epublish

Résumé

Pregnancies in patients with complement gene variant-mediated thrombotic microangiopathy (cTMA) are challenging, and pregnancies in such patients after kidney transplantation (KTX) are even more so. We identified nine pregnancies following KTX of three genetically high-risk cTMA patients enrolled in the Vienna thrombotic microangiopathy cohort. Preventive plasma therapy was used in three pregnancies, and one patient had ongoing eculizumab (ECU) therapy during two pregnancies. Seven out of nine pregnancies (78%) resulted in the delivery of healthy children. The other two included one early abortion at gestational Week 12 during ongoing ECU therapy and one late foetal death at gestational Week 33 + 3, most likely not related to complement dysregulation. Kidney transplant function after delivery remained stable in all but one pregnancy. In the aforementioned case, a severe cTMA flare occurred after delivery despite use of preventive plasma infusions. Kidney graft function could be rescued in this patient by ECU. As such, successful pregnancies can be accomplished in kidney transplant recipients (KTRs) with a history of cTMA. We used preemptive plasma therapy or ongoing ECU treatment in selected cases. Thus, becoming pregnant can be encouraged in KTRs with native kidney cTMA. Extensive preconception counselling, however, is mandatory in such cases.

Sections du résumé

BACKGROUND BACKGROUND
Pregnancies in patients with complement gene variant-mediated thrombotic microangiopathy (cTMA) are challenging, and pregnancies in such patients after kidney transplantation (KTX) are even more so.
METHODS METHODS
We identified nine pregnancies following KTX of three genetically high-risk cTMA patients enrolled in the Vienna thrombotic microangiopathy cohort. Preventive plasma therapy was used in three pregnancies, and one patient had ongoing eculizumab (ECU) therapy during two pregnancies.
RESULTS RESULTS
Seven out of nine pregnancies (78%) resulted in the delivery of healthy children. The other two included one early abortion at gestational Week 12 during ongoing ECU therapy and one late foetal death at gestational Week 33 + 3, most likely not related to complement dysregulation. Kidney transplant function after delivery remained stable in all but one pregnancy. In the aforementioned case, a severe cTMA flare occurred after delivery despite use of preventive plasma infusions. Kidney graft function could be rescued in this patient by ECU. As such, successful pregnancies can be accomplished in kidney transplant recipients (KTRs) with a history of cTMA. We used preemptive plasma therapy or ongoing ECU treatment in selected cases.
CONCLUSIONS CONCLUSIONS
Thus, becoming pregnant can be encouraged in KTRs with native kidney cTMA. Extensive preconception counselling, however, is mandatory in such cases.

Identifiants

pubmed: 33841869
doi: 10.1093/ckj/sfaa113
pii: sfaa113
pmc: PMC8023217
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1255-1260

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

Références

Nephrol Dial Transplant. 2016 Dec;31(12):2122-2130
pubmed: 27587606
Am J Obstet Gynecol. 2008 Aug;199(2):98-104
pubmed: 18456236
Eur J Intern Med. 2020 Mar;73:51-58
pubmed: 31791575
Clin Kidney J. 2019 Apr 21;12(3):333-337
pubmed: 31198225
Blood. 2014 Jul 10;124(2):211-9
pubmed: 24859360
Kidney Med. 2020 Feb 22;2(2):213-217
pubmed: 32734241
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Am J Transplant. 2011 Nov;11(11):2388-404
pubmed: 21794084
Nephrol Dial Transplant. 2020 Sep 1;35(9):1538-1546
pubmed: 30805631
Am J Kidney Dis. 2019 Nov;74(5):675-681
pubmed: 31221529
N Engl J Med. 2013 Oct 3;369(14):1379-80
pubmed: 24088105
J Am Soc Nephrol. 2018 Mar;29(3):1020-1029
pubmed: 29282226
Am J Transplant. 2009 Jul;9(7):1541-9
pubmed: 19459800
Kidney Int. 2018 Feb;93(2):450-459
pubmed: 28911789
N Engl J Med. 2014 Aug 14;371(7):654-66
pubmed: 25119611
J Am Soc Nephrol. 2010 May;21(5):859-67
pubmed: 20203157
J Am Soc Nephrol. 2014 May;25(5):1103-9
pubmed: 24525032

Auteurs

Natalja Haninger-Vacariu (N)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Christof Aigner (C)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Martina Gaggl (M)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Renate Kain (R)

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Zoltán Prohászka (Z)

3rd Department of Internal Medicine, Research Laboratory, MTA-SE Research Group of Immunology and Hematology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Georg A Böhmig (GA)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Raute Sunder-Plassmann (R)

Department of Laboratory Medicine, Genetics Laboratory, Medical University of Vienna, Vienna, Austria.

Gere Sunder-Plassmann (G)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Alice Schmidt (A)

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

Classifications MeSH